Introduction
Invasive fungal infections (IFIs) in recipients of allogeneic blood and marrow transplantation (allo-BMT) have a higher mortality rate than in other immunocompromised hosts, and are recognized as the leading infectious cause of mortality. [1] [2] [3] [4] [5] For this reason, primary antifungal prophylaxis to prevent the occurrence of life-threatening IFI in allo-BMT recipients has been established by professional guidelines and clinical practice as a standard antifungal strategy in this setting. [6] [7] [8] Fluconazole has been used for antifungal prophylaxis for more than a decade, improving the outcome of allo-BMT recipients through an effective reduction of the incidence of invasive Candida infections. [9] [10] [11] For nearly as long, and in the context of a changing epidemiology, the challenge remained to identify antifungal agents with a good safety profile that could successfully prevent mould infections, in particular invasive pulmonary aspergillosis (IPA), and reduce fungal-related mortality. 2, 3, [12] [13] [14] [15] [16] Posaconazole is a new-generation triazole agent with a favourable toxicity profile and an extended spectrum of antifungal activity that includes species of Candida, Aspergillus, Zygomycetes and Fusarium. 17 The results from two large prospective randomized trials have granted posaconazole FDA and EMEA approval in patients with neutropenia after AML-type chemotherapy and GVHD after allo-BMT, 18, 19 and have positioned this new triazole as the recommended antifungal prophylactic agent in these clinical settings for a number of professional groups. [6] [7] [8] Despite this evidence, a question remains whether these encouraging results would translate onto other populations of patients at high risk of IFI. In particular, no data have been provided so far about the use of primary prophylaxis with posaconazole in allo-BMT, in the absence of GVHD. In this study, we present the first report on the efficacy and safety of posaconazole primary antifungal prophylaxis in allo-BMT recipients during the early neutropenic phase until engraftment and up to 100 days post transplant. Our results suggest that posaconazole antifungal prophylaxis, compared with itraconazole, may reduce the incidence of invasive fungal disease (IFD), and improve IFD-free survival (FFS) and OS in this clinical setting. 18, 19 our local antifungal policy committee, with representatives from the Hospital Pharmacy and the Departments of Haematology and Infectious Diseases, decided to change antifungal prophylaxis to posaconazole oral solution (200 mg three times daily). In addition to prolonged neutropenia and GVHD, posaconazole was adopted into our clinical protocol during allo-BMT in the absence of GVHD, with a commitment to prospectively auditing this experience and to compare it with our previous experience with itraconazole in this particular clinical setting. Allo-BMT antifungal prophylaxis in our centre was administered, regardless of the antifungal agent used, to cover both the post transplant neutropenic phase and the early post-engraftment phase, up to 100 days post transplantation, and discontinued at this point in the absence of GVHD. Patients with a previous history of IFI, on secondary antifungal prophylaxis or active treatment with other non-topical antifungal drugs up to 4 weeks before allo-BMT, were excluded from the study. Participants were all adults (418 years) and had signed informed consents for treatment and data collection. The study was approved by our local clinical research ethics committee (CEIC Bellvitge; EPA 008/08).
Patients and methods

Patients and study design
The standards of protective environment, including single rooms with laminar flow or HEPA filters, recommendations for hand, skin and oral hygiene and low microbial content diet did not significantly change throughout the study period. No antibacterial prophylaxis was administered to our allo-BMT recipients. Management of febrile neutropenia included chest X-ray, urine and blood cultures and empiric antibiotic treatment on the first day of neutropenic fever. High-resolution computed tomography of the thorax was performed when unexplained fever persisted over 72 h, despite empirical antibiotic therapy or when any clinical signs or symptoms developed. In the case of radiological chest abnormalities and no other microbiological evidence elsewhere, bronchoscopy with bronchoalveolar lavage was performed whenever possible for microbiological testing, including galactomannan detection. Galactomannan test was performed in peripheral blood samples twice weekly, and defined positive as an optical index X0.5 in two consecutive blood samples or a single bronchoalveolar lavage fluid sample (Platelia Aspergillus enzyme-linked immunosorbent assay; Bio-Rad Laboratories, Madrid, Spain). Additional blood, sputum or other relevant samples were cultured from possible infected sites when clinically indicated.
Primary end point of our analysis was the incidence of probable or proven breakthrough IFD as defined according to the 2008 criteria of the European Organization for Research and Treatment of Cancer (EORTC). 20 Other efficacy end points were the probabilities of FFS and OS, incidence of fever, persistent fever unresponsive to broadspectrum antibiotic treatment for X72 h, antifungal drug toxicity, classified according to the Common Toxicity Criteria grading system of the NCI (version 2.0, Bethesda, 1999), and prophylaxis failure, defined as an early discontinuation of prophylaxis before the fixed 100-day treatment period for a clinical decision of suspected lack of efficacy. As opposed to the definition of IFD for end-point analysis, which follows EORTC criteria, real-life clinical decisions to replace primary prophylaxis with i.v. antifungal therapy relied in all cases on an individualized clinical judgement (for example, patient general condition, signs and symptoms, test results and treatment compliance), rather than on the fulfilment of EORTC IFD criteria, which were not developed to fit this daily clinical practice purpose. [20] [21] [22] Persistent fever was considered too unspecific to trigger a change in antifungal treatment on its own. 23 Neither itraconazole nor posaconazole drug level monitoring were available during this study to guide clinical decisions. Short-term bridging with i.v. antifungals for oral intolerance to posaconazole was not planned upfront in this observational audit. The occurrence and reasons for early discontinuation of prophylaxis were recorded in all cases. Data on demographic and baseline characteristics, clinical features and follow-up, diagnostic tests and changes in antimicrobial treatments were recorded in a specific database. Clinical outcomes were evaluated for a fixed prophylaxis period of 100 days post transplant.
Statistical analysis
Software packages SPSS (version 13; http://www.spss.com) and R (http://www.r-project.org) were used for statistical analysis, which followed the guidelines established in 2003 by the EBMT, including the analysis of cumulative incidence of prophylaxis failure and probable or proven IFD vs death as a competing risk, compared with Gray test. 24 The probability of FFS is an EFS curve, in which the events of interest are death and proven or probable IFD, so that the FFS curve shows the decreasing probability of being alive and without IFD (fungal-free) during the fixed treatment period. All reported P-values are two-sided and were accepted as statistically significant if o0.05. Table 1 . In vivo T-cell depletion with either alemtuzumab for reduced-intensity allo-BMT (100 mg i.v. divided into 5 doses, days À8 to À4) or ATG for myeloablative allo-BMT (7.5 mg/kg i.v. divided into 3 doses, days À3 to À1) was more frequent for patients in the posaconazole group (39 vs 0%; P ¼ 0.003). There were no other statistically significant differences in patient and transplant characteristics.
Three patients in the posaconazole group had primary engraftment failure, defined as ANC not reaching X500/mL by day þ 28. They all had AML in first CR at allo-BMT. The first patient was a 23-year-old woman who received a single umbilical cord blood unit allo-BMT (HLA match 5/6; 1.52 Â 10 5 /kg CD34 þ cells and 2.2 Â 10 7 /kg nucleated cells) following the Spanish Pethema protocol. 25 Postthawing cell viability (CD34 þ and total nucleated cells) was low (40%), and BM chimerism on day þ 15 showed only 16% donor cells. Temporary CYA discontinuation improved cord chimerism, the patient engrafted neutrophils on day þ 49, and reached full donor chimera in the marrow and in peripheral blood lymphoid and myeloid subsets on day þ 62. The second case was a 50-year-old man receiving a reduced-intensity allo-BMT from his HLA-identical sister, who mobilized suboptimally, providing a total dose of 3.1 Â 10 6 /kg CD34 þ cells after four apheresis procedures. This patient had only a minor delay in neutrophil engraftment to day þ 33. Finally, the third case was a 58-year-old woman who received a reduced-intensity allo-BMT with cryopreserved peripheral blood progenitors from an older HLA-identical sister. Post-thawing colonyforming units growth were poor, and the patient required a second infusion from the same donor with a total of 8 Â 10 6 /kg CD34 þ cells after ATG and CYA. She engrafted on day þ 53, 11 days after the second stem cell infusion. These patients stayed on posaconazole prophylaxis for the whole duration of neutropenia, had no IFD, and remained alive and in maintained CR at the end of the observation period (day þ 100), and also at their most recent follow-ups, more than 18 months post transplant in all three cases. Other than these cases with graft failure, time to engraftment was virtually identical between posaconazole and itraconazole groups (16.5 ± 3.1 vs 16.1±2.7, respectively; P ¼ 0.647). In addition, the incidence of acute GVHD grade II-IV was comparable between groups (33% for all cases; 44% in itraconazole vs 27% in posaconazole; P ¼ 0.249).
Itraconazole administration started as an oral suspension in all patients, with a low threshold to change onto i.v. route based on patient tolerance. In fact, all patients on itraconazole received i.v. drug for the majority of their in-patient admission for allo-BMT and resumed oral suspension at discharge. Retrospective analysis of this cohort does not allow to clearly dissecting real intolerance to oral itraconazole from patient's or physician's preference. In the case of posaconazole, two patients had the drug discontinued for liver function test abnormalities (grade 3 bilirubin and transaminases) that normalized 1 and 2 weeks after stopping the drug, which could be subsequently restarted without toxicity recurrence. Laboratory safety details during the observation period were comparable for both antifungal agents (Figure 1 and Supplementary data). Only one patient had to stop posaconazole prophylaxis for grade 3 gastrointestinal symptoms (that is, diarrhoea). Five additional posaconazole cases had grade X3 oral mucositis. In keeping with the recommendations from our nutrition support team, these patients started enteral nutrition through a nasogastric tube, and continued to receive oral suspension posaconazole three times daily immediately after the enteral feeding through the nasogastric tube, which has been examined as a feasible alternative to standard oral administration in healthy volunteers. 26 Other minor side effects reported, such as nausea or vomiting and headaches, were more difficult to attribute to posaconazole and resolved with no need for drug discontinuation.
A total of 41 patients (84%) presented at least one episode of fever during the study period. Thirteen of these Posaconazole prophylaxis in allogeneic BMT I Sánchez-Ortega et al 41 patients (27% of all cases) had persistent fever for longer than 72 h (five itraconazole cases and eight posaconazole cases). The median duration of fever was 4 days (mean 6.8 days; range 0-36). The commonest microbiological isolates were coagulase-negative Staphylococcus (52%), Klebsiella (12%), Escherichia coli (12%), Staphylococcus aureus (8%) and other Gram-negative bacteria (16%). The commonest sources of bacterial infection were central venous catheters and lower respiratory tract infections. Twenty-one patients (43%) did not have any microbiological isolates in relation with their febrile episodes. There were no statistical differences between itraconazole and posaconazole groups in terms of the incidence of fever, persistent fever and fever total duration (Table 2) . Five patients on itraconazole (31%) and five on posaconazole (15%) discontinued prophylaxis and started i.v. antifungal treatment as a clinical decision in the context of persistent fever unresponsive to broad-spectrum antibiotic treatment for X72 h (defined as prophylaxis failure; no difference between groups, P ¼ 0.246). Time of exposure to antifungals for all patients and time on oral prophylaxis to first use of empirical antifungal therapy in these 10 patients (Table 2) showed no statistical differences between patients receiving itraconazole and posaconazole. Only two patients, both on itraconazole prophylaxis had an EORTC diagnosis of probable or proven IFD, both cases of IPA. Cumulative incidence of breakthrough proven or probable IFD during the 100-day study period was significantly lower in patients receiving posaconazole prophylaxis than in their itraconazole counterparts (0 vs 12%; P ¼ 0.04; Figure 2 ). These two IPA cases were both male, aged 42 and 48 years old, with diagnoses of AML and CML. They had both received an HLA-identical sibling myeloablative allo-BMT. The first case had a dense well-circumscribed single nodule without a clear halo-sign on a first chest computed tomography scan, which additionally cavitated The second case was diagnosed with probable IPA on day þ 29, 11 days after neutrophil engraftment, based on radiological findings (initial computed tomography scan with unspecific lung infiltrates including several small nodules, and subsequent air-crescent sign in the same episode) and positive galactomannan test in serum (index 0.63) and the bronchoalveolar lavage (index 1.1) in the context of persistent fever refractory to wide-spectrum antibiotics and removal of the central catheter, and was also treated with voriconazole. Eight additional cases received either caspofungin (n ¼ 4) or lipid formulations of amphotericin B (n ¼ 4) as empiric treatment based on clinical decision, and for whom probable or proven IFD was not subsequently confirmed. Finally, patients on posaconazole antifungal prophylaxis had a significantly higher FFS (91 vs 56%; P ¼ 0.003; Figure 3 ) and OS (91 vs 63%; P ¼ 0.011; Figure 4 ) than patients who received itraconazole prophylaxis.
Discussion
As a general antifungal strategy, primary prophylaxis reduces all-cause mortality, IFI-related mortality and documented IFI in allo-BMT, and should be used for all allo-BMT recipients according to a recent systematic review and meta-analysis of 64 randomized controlled trials. 27 Despite the encouraging results of primary antifungal prophylaxis with posaconazole for AML and GVHD patients, there are currently no data on whether this experience would translate onto the use of posaconazole for antifungal prophylaxis in the early phase of allo-BMT in the absence of GVHD. Here, we present the first study analysing primary antifungal prophylaxis with posaconazole in the early phase of allo-BMT, and comparing it to itraconazole prophylaxis. This is an observational study, a prospective and retrospective audit of our experience in this setting at the Catalan Institute of Oncology in Barcelona, Spain. The study includes all consecutive patients complying with inclusion and exclusion criteria. As for any other Figure 3 Invasive fungal disease-free survival during the 100-day fixed prophylaxis period. The invasive fungal disease-free survival for the whole group was 80%, 56% in the itraconazole group and 91% in the posaconazole group (P ¼ 0.003; log rank). Data were censored on day þ 100 post transplant.
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Posaconazole prophylaxis in allogeneic BMT I Sánchez-Ortega et al observational single-centre non-randomized sample, the study population is somewhat heterogeneous and changes over time along with clinical practice. Even so, the standards of protective isolation and the availability of diagnostic tests did not change during the study period, and there were no differences between groups in terms of engraftment or incidence of acute GVHD.
Patients on posaconazole had a reduced cumulative incidence of IFD, and an increased FFS and OS during the study period, compared with their itraconazole counterparts. As expected, there were no differences between groups in terms of incidence of fever, persistent fever, fever duration, bacterial isolates or infection source. Reassuringly, none of the patients with persistent fever in the posaconazole group who remained on prophylaxis rather than starting treatment (three out of eight) ended up developing an IFD. Posaconazole was overall well tolerated, included a few patients with mucositis who received it after enteral feeding through nasogastric tubes. Toxicity profiles for both azoles have been reported at length and analysed in larger patient populations. Our results reproduce that most posaconazole side effects were minor and not different from those with itraconazole.
In summary, our results show that in addition to prolonged neutropenia and GVHD, antifungal prophylaxis with posaconazole, as compared with itraconazole, may reduce the incidence of IFD and improve the outcome of patients after allo-BMT. Undoubtedly, the evidence from an observational non-randomized single-centre study, such as our own, has caveats. In addition, local characteristics, such as fungal epidemiology, incidence of IFD and costeffectiveness, to mention only a few, must be reviewed and incorporated into the algorithms to manage IFI in allo-BMT recipients in individual centres. Nevertheless, and in the absence of randomized trials with posaconazole in this indication, our single-centre study provides the first direct supporting evidence to explore its use in this important clinical setting.
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